What HB 1332 does: Requires hospitals and healthcare facilities receiving state funds to prefer American-manufactured pharmaceuticals. Exceptions apply when domestic drugs are unavailable, would jeopardize patient safety, are needed during emergencies, or cost more than 20% higher. DCH enforces the law, and noncompliance can result in loss of state funding eligibility.
Consumer impact: While the bill aims to strengthen domestic drug supply chains, requiring a domestic sourcing preference could increase pharmaceutical costs for hospitals, particularly safety-net and rural hospitals that rely heavily on state funds and often use lower-cost generic medications manufactured overseas. Cost increases could be passed through to patients.